SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):327P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Chen, L.-C.
Right arrow Articles by Ting, G.
PubMed
Right arrow Articles by Chen, L.-C.
Right arrow Articles by Ting, G.

Oncology-Basic Science: Therapy, Metrics & Intervention

Therapy, Metrics & Intervention Posters

Therapeutic efficacy of bimodality nanotargeted 188Re-(DXR)-liposome in a C26 colon carcinoma ascites mouse model

Liang-Cheng Chen1, Chih-Hsien Chang1, Chia-Yu Yu1, Ya-Jen Chang1, Yu-Hsien Wu1, Wan-Chi Lee1, Chung-Hsin Yeh1, Te-Wei Lee1 and Gann Ting2

1 Institute of Nuclear Energy Research, Taoyuan, Taiwan; 2 National Health Research Institutes, Miaoli, Taiwan

1385

Objectives: The aim of this study was to investigate the therapeutic efficacy of intraperitoneally (i.p.) injected bimodality nanotargeted 188Re-labeled pegylated liposome (188Re-liposome) or liposomal doxorubicin (188Re-DXR-liposome) in the C26 murine colon carcinoma ascites mouse model.

Methods: The biodistribution, pharmacokinetics and micro-SPECT/CT imaging of 188Re-DXR-liposome after i.p. injection were performed in ascites pervading C26 colon cancer mice. The maximum tolerated dose of i.p. injected 188Re-(DXR)-liposome was performed in normal BALB/c mice. The efficacy of 188Re-DXR-liposome (22.2 MBq with 5 mg/kg DXR) was compared with 188Re-liposome (22.2 MBq), Lipo-Dox (5 mg/kg DXR) and normal saline by a single-dose treatment in ascites tumor-bearing mice. Furthermore, the survival and ascites inhibition of mice after treatment were evaluated.

Results: The median survival times of mice that received an i.p. injection of 188Re-liposome, Lipo-Dox or normal saline were 23.3, 22.2 and 19.3 d, respectively, after tumor inoculation. Mice treated with 188Re-DXR-liposome had a median survival time of 29.3 d, which was statistically significant when compared with other treatments (P = 0.0004). The inhibition of ascites (decrease 91% at 4 d after treatment; P < 0.05) and survival data demonstrated a benefit and survival advantage of bimodality nanotargeted 188Re-DXR-liposome after i.p. administration in mice.

Conclusions: These results indicate that i.p. administration of 188Re-DXR-liposome has a radiochemo-bimodality combination synergistic effect in the murine ascites animal model providing a benefit considering the nanoliposome simultaneous delivery a combination of systemic targeted radiotherapy and chemotherapy in clinical usage.





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Chen, L.-C.
Right arrow Articles by Ting, G.
PubMed
Right arrow Articles by Chen, L.-C.
Right arrow Articles by Ting, G.